Prevalence of monoclonal gammopathy of undetermined significance in black South African men.

Authors

null

Kara Ilene Cicero

NYP/Columbia, New York, NY

Kara Ilene Cicero , Maureen Joffe , Moosa Patel , Audrey Pentz , Paul Ruff , Suzanne Lentzsch , Siyang Leng , Codruta Chiuzan , Judith Jacobson , Timothy Rebbeck , Alfred I. Neugut

Organizations

NYP/Columbia, New York, NY, University of Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa, Chris Hani Baragwanath Academic Hospital and University of the Witwatersrand, Johannesburg, South Africa, Witshealth, Sandton, South Africa, Columbia University, New York, NY, Home, Sunnyside, NY, Northwell Health, New York, NY, Division of Population Sciences, Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health, Boston, MA, Columbia University Herbert Irving Comprehensive Caner Center, New York, NY

Research Funding

U.S. National Institutes of Health

Background: Monoclonal gammopathy of undetermined significance (MGUS) is the precursor to multiple myeloma (MM). MM disproportionately affects black individuals, but the cumulative risk of progression from MGUS to malignancy does not differ by race. Hence, the racial disparities in MM incidence appear to arise from differences in the occurrence of MGUS. Nonetheless, MGUS has been studied mainly in white populations; the study that first described the natural history of MGUS was conducted by Kyle, et al. (2006) in 97.3% white Olmsted County, Minnesota. Methods: We determined the prevalence of MGUS among black South African men >30 years of age at the Chris Hani Baragwanath Academic Hospital in Johannesburg. We conducted serum protein electrophoresis (SPEP) and free light chain (FLC) quantification and used the same criteria for MGUS as the Olmsted County studies: a monoclonal protein on SPEP or an abnormal FLC-ratio plus elevation in the appropriate FLC. We also investigated the association between MGUS and various clinical and behavioral factors. Results: The prevalence of MGUS in our cohort (n=386) was 8.03% (95%CI 5.32-10.74), nearly 1.6-fold higher than in Olmsted County males. In a univariable logistic regression model, MGUS was associated with HIV status (odds ratio (OR) 2.39, 95%CI 0.95-5.51), but in the adjusted model that also included body mass index (BMI) and cigarette use, the magnitude of the association decreased to an OR of 2.17 and was not statistically significant. MGUS was associated with current (vs. never) cigarette smoking in both univariable (OR 5.2, 95%CI 1.53-24.0) and multivariable (OR 4.11, 95%CI 1.08-20.4) models. Conclusions: Not only did we find the prevalence of MGUS in black South African men to be substantially higher than in white populations, but we also report that MGUS cases are associated with potentially modifiable risk factors. Building on this pilot study, a larger study is currently underway powered to confirm the relationship between MGUS and HIV, as well as between MGUS and cigarette smoking, in a black African population inclusive of both genders. Future studies designed to evaluate genetic and matched-environmental contributions may elucidate racial disparities and facilitate the development of strategies to prevent plasma cell malignancies.


MGUS+

N (%)
MGUS-

N (%)
Univariable

OR [95% CI]
p-value
Multivariable*

OR [95% CI]
p-value
Total
31
(8.0)
355
(92.0)




HIV – infected
8
(26.6)
45
(13.2)
2.39 [0.95, 5.51]
0.05*
2.17 [0.66, 6.59]
0.18
HIV – uninfected
22
(73.3)
296
(86.8)
ref

ref

Mean BMI (SD)
24.87
(5.15)
27.04
(5.62)
0.92 [0.85, 0.99]
0.04*
0.96 [0.85, 1.08]
0.52
Cigarette – active
11
(57.9)
45
(25.4)
5.21 [1.53, 24.03]
0.02*
4.11 [1.08, 20.40]
0.05
Cigarette – former
5
(26.3)
68
(38.4)
1.57 [0.37, 7.90]
0.55
1.53 [0.35, 7.88]
0.58
Cigarette – never
3
(15.8)
64
(36.2)
ref

ref

*Covariates with p<0.15 were included in the multivariable model.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Plasma Cell Disorders

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr e20032)

DOI

10.1200/JCO.2022.40.16_suppl.e20032

Abstract #

e20032

Abstract Disclosures